---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019766"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:51:53.777715+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NextCure discontinues NC762, prioritizes LNCB74 ADC; NC410 data expected H1 2024

## Summary
- NC410 (LAIR-2 fusion) combination with pembrolizumab adding patients to 100 mg cohort for microsatellite stable colorectal cancer without liver mets; data expected H1 2024.
- NC762 (B7-H4 mAb) development halted due to competitive environment and limited activity; resources shifted to LNCB74 (B7-H4 ADC).
- LNCB74 set to initiate dose range-finding toxicology study and GMP manufacturing in early 2024.
- NC525 (LAIR-1 mAb) Phase 1a dose escalation ongoing (4th cohort enrolled); safe and well tolerated; data expected H1 2024.

## SEC filing metadata
- accession: 0001558370-23-019766
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837023019766/0001558370-23-019766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837023019766/nxtc-20231214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019766
- JSON: https://secwatch.observer/filing/0001558370-23-019766.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.